A recently completed phase II trial has reported inferior outcome for EGFR-mutated NSCLC patients co-treated with erlotinib and linsitinib (IGF1R-directed TKI, OSI-906) compared to erlotinib alone [50]. This evidence concerns the gene IGF1R and non-small cell lung carcinoma.